Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 654 of 6351
-
A tablet test aims to catch hidden attention and memory problems after stroke
Diagnosis CompletedStroke is one of the most common long-term disabilities in the world. Despite better access to more effective acute treatment, WHO reports a prediction of almost a doubling of disability-adjusted life-years (DALYs) in 2050. In UK about 100 000, in Sweden about 20,000 people suffe…
Sponsor: Umeå University • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
Phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New antibody takes aim at Hard-to-Treat liver cancer
Disease control Recruiting nowThis research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a shot and a vaccine free people with HIV from daily pills? early trial aims to find out.
Disease control Recruiting nowThis is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load …
Phase 1 • Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Leukemia transplant study tests lower radiation for better outcomes
Disease control Recruiting nowThis is a randomized phase II trial of standard-of-care reduced-intensity conditioning (RIC) with 200 versus 400 cGy of total body irradiation (TBI) in patients with acute leukemia undergoing first allogeneic blood or marrow Transplantation (BMT). The primary objective is to comp…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New model aims to eliminate HIV transmission from mothers to infants in malawi
Prevention Recruiting nowPurpose: To conduct a hybrid effectiveness-implementation stepped-wedge trial to: 1. Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of infants who receive timely EID testing. 2. Estimate the effect of the PAC-Man model, compared to SOC, on the propo…
Sponsor: University of North Carolina, Chapel Hill • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
Could the sound of your voice reveal depression?
Diagnosis CompletedA prospective, single arm, non-randomized, pivotal clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made by a clinician using the Structured Clinical Inte…
Sponsor: Kintsugi Mindful Wellness, Inc. • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Genetic test guides statin use to prevent heart attacks
Prevention OngoingThis research investigates the potential advantages of intensive preventive statin treatment for healthy men aged 45-80 and women aged 55-80 who possess a high genetic predisposition to coronary artery disease (CAD). By specifically targeting the top 20% of individuals with eleva…
Phase 4 • Sponsor: Mikk JÜRISSON • Aim: Prevention
Last updated Jun 27, 2026 12:34 UTC
-
New drug cocktail shows promise for Tough-to-Treat stomach cancer
Disease control Recruiting nowThis is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
Phase 2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a lower drug dose make stem cell transplants safer?
Disease control Recruiting nowCyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant. The standard dose of this medicine is 50 mg per kg of the patient's weight given o…
Phase 2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can neighborhood cleanups curb Mosquito-Borne viruses?
Prevention Recruiting nowArboviral diseases are viral diseases transmitted by mosquitoes of the Aedes genus and are constantly spreading throughout the world, constituting a significant threat to public health. In Africa, there is very little data on the epidemiological situation of Aedes-borne diseases…
Sponsor: Institute of Tropical Medicine, Belgium • Aim: Prevention
Last updated Aug 21, 2026 00:00 UTC
-
Could cord blood cells tame tough lupus?
Disease control Recruiting nowThe purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.
Early phase 1 • Sponsor: Chengdu Ucello Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for hemophilia patients with inhibitors: STSP-0601 enters phase 3 trial
Disease control OngoingThis study will assess the efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor
Phase 3 • Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Virtual hope box aims to curb suicide in High-Risk veterans
Symptom relief Recruiting nowThis study will test whether a novel intervention, Virtual Hope Box Enhanced Facilitation (VHB-EF), reduces suicide risk in Veterans after discharge from inpatient psychiatric hospitalization. Additionally, this study will also conduct interviews with Veterans and healthcare prov…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can a common supplement help ALS patients stay independent longer?
Disease control Recruiting nowPhase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the efficacy of ALCAR (two different dosages wil…
Phase 2/3 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Breathe in protection: inhaled COVID vaccine trial launches
Vaccine Recruiting nowThe goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the exp…
Phase 2 • Sponsor: McMaster University • Aim: Vaccine
Last updated Jun 27, 2026 08:14 UTC
-
New drug cocktail aims to beat deadly fungus in blood cancer patients
Disease control Recruiting nowThis clinical trial, a single-arm prospective study, aims to evaluate the efficacy and safety of liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole in treating adult patients with malignant hematological diseases complicated by mucormycosis. The pri…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug shows promise against rare liver virus
Disease control OngoingThis is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed …
Phase 2/3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New trial aims to stop phantom limb pain before it starts
Prevention Recruiting nowBackground: Most amputees experience phantom limb pain (PLP), for years after amputation. Virtually all PLP research to date has focused on the mechanisms of chronic PLP, ignoring the mechanisms of chronification. This research project will focus on combined neuromodulatory inter…
Sponsor: University of Haifa • Aim: Prevention
Last updated Jun 26, 2026 14:57 UTC
-
New combo therapy aims to boost surgery success in pancreatic cancer
Disease control Recruiting nowPancreatic cancer is a highly malignant digestive system tumor with a very poor prognosis. In recent years, both the incidence and mortality rates of pancreatic cancer have shown a marked upward trend worldwide. Global cancer statistics from 2020 indicate that approximately 495,0…
Phase 2 • Sponsor: Ningbo Medical Center Lihuili Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC